These information suggested that HCC cells or tumor with high expression of YRDC, containing higher basal activity of the MEK/ERK, might be more sensitive, or responsive, to lenvatinib, and that those with low expression of YRDC might be resistant to lenvatinib. Here, MAP2K7 is linked to hepatocellular carcinoma.